Search

Search Constraints

You searched for: Author/Creator Narang, Amol

Search Results

1. 812 Urelumab (anti-CD137 agonist) in combination with vaccine and nivolumab treatments is safe and associated with pathologic response as neoadjuvant and adjuvant therapy for resectable pancreatic cancer. (9th November 2020)

2. Development, Practice Patterns, and Early Clinical Outcomes of a Multidisciplinary Liver Cancer Clinic. (21st April 2021)

3. High local failure rates despite high margin‐negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients treated with stereotactic body radiation therapy following multi‐agent chemotherapy. (10th February 2022)

5. Establishing a Deaf and American Sign Language Inclusive Residency Program. (18th February 2022)

7. Building a learning network to accelerate improvement in pancreas cancer care and outcomes: Canopy Cancer Collective. Issue 28 (1st October 2022)

8. Risk of Pancreatic Cancer in the Long-Term Prospective Follow-Up of Familial Pancreatic Cancer Kindreds. (27th August 2022)

9. Margin negative resection and pathologic downstaging with multiagent chemotherapy with or without radiotherapy in patients with localized pancreas cancer: A national cancer database analysis. (March 2021)

10. Demonstrating the benefits of corrective intraoperative feedback in improving the quality of duodenal hydrogel spacer placement. Issue 7 (18th April 2022)